WO2010062038A2 - 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 - Google Patents
티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2010062038A2 WO2010062038A2 PCT/KR2009/006050 KR2009006050W WO2010062038A2 WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2 KR 2009006050 W KR2009006050 W KR 2009006050W WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isomer
- tyrosine kinase
- pharmaceutical composition
- composition containing
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Abstract
본 발명은 하기 화학식 1로 표시되는 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염에 관한 것이다. 화학식 1의 화합물은 디스코이딘 도메인 리셉터 1(DDR1)과 디스코이딘 도메인 리셉터 2(DDR2)의 티로신 키나아제 활성을 억제할 수 있어 암, 간경화증, 동맥경화, 류마티스 관절염, 골 관절염 등 디스코이딘 도메인 리셉터 1 혹은 디스코이딘 도메인 리셉터 2의 과다 활성화가 주요 원인으로 알려진 질환을 예방 또는 치료하는데 유용하게 사용될 수 있다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080118850A KR101126736B1 (ko) | 2008-11-27 | 2008-11-27 | 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 |
KR10-2008-0118850 | 2008-11-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010062038A2 true WO2010062038A2 (ko) | 2010-06-03 |
WO2010062038A3 WO2010062038A3 (ko) | 2010-07-22 |
Family
ID=42226201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/006050 WO2010062038A2 (ko) | 2008-11-27 | 2009-10-20 | 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101126736B1 (ko) |
WO (1) | WO2010062038A2 (ko) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130072482A1 (en) * | 2010-05-26 | 2013-03-21 | Beom-Seok Yang | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same |
CN103087077A (zh) * | 2011-11-03 | 2013-05-08 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2013068836A1 (en) | 2011-11-07 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
JP2013538223A (ja) * | 2010-09-15 | 2013-10-10 | エフ.ホフマン−ラ ロシュ アーゲー | アザベンゾチアゾール化合物、組成物及び使用方法 |
CN103360407A (zh) * | 2012-04-10 | 2013-10-23 | 上海希迈医药科技有限公司 | 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
JPWO2015060373A1 (ja) * | 2013-10-23 | 2017-03-09 | 中外製薬株式会社 | キナゾリノンおよびイソキノリノン誘導体 |
WO2018171726A1 (zh) * | 2017-03-23 | 2018-09-27 | 高雄医学大学 | 盘基蛋白结构域受体1的抑制剂及活化剂及其用途 |
WO2021239643A1 (en) | 2020-05-25 | 2021-12-02 | Chiesi Farmaceutici S.P.A. | Benzylamine derivatives as ddrs inhibitors |
EP4032896A1 (en) | 2021-01-20 | 2022-07-27 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof |
WO2023210599A1 (ja) * | 2022-04-25 | 2023-11-02 | 日本新薬株式会社 | Ddr1キナーゼ阻害剤としての化合物および医薬 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101540051B1 (ko) * | 2013-11-27 | 2015-07-28 | 한국과학기술연구원 | 피부 노화 방지 또는 피부 상태 개선용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
WO1997013771A1 (en) * | 1995-10-11 | 1997-04-17 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
KR20010031908A (ko) * | 1997-11-11 | 2001-04-16 | 실버스타인 아써 에이. | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 |
US20040019065A1 (en) * | 2002-03-01 | 2004-01-29 | Romines William Henry | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
-
2008
- 2008-11-27 KR KR1020080118850A patent/KR101126736B1/ko active IP Right Grant
-
2009
- 2009-10-20 WO PCT/KR2009/006050 patent/WO2010062038A2/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
WO1997013771A1 (en) * | 1995-10-11 | 1997-04-17 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
KR20010031908A (ko) * | 1997-11-11 | 2001-04-16 | 실버스타인 아써 에이. | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 |
US20040019065A1 (en) * | 2002-03-01 | 2004-01-29 | Romines William Henry | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130072482A1 (en) * | 2010-05-26 | 2013-03-21 | Beom-Seok Yang | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same |
US9062066B2 (en) * | 2010-05-26 | 2015-06-23 | Korea Institute Of Science And Technology | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same |
JP2013538223A (ja) * | 2010-09-15 | 2013-10-10 | エフ.ホフマン−ラ ロシュ アーゲー | アザベンゾチアゾール化合物、組成物及び使用方法 |
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
CN103087077B (zh) * | 2011-11-03 | 2016-05-18 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2013064068A1 (zh) * | 2011-11-03 | 2013-05-10 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
CN103087077A (zh) * | 2011-11-03 | 2013-05-08 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2013068836A1 (en) | 2011-11-07 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
CN103360407A (zh) * | 2012-04-10 | 2013-10-23 | 上海希迈医药科技有限公司 | 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
CN103360407B (zh) * | 2012-04-10 | 2016-06-22 | 上海希迈医药科技有限公司 | 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
EP3061749A4 (en) * | 2013-10-23 | 2017-05-31 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
JPWO2015060373A1 (ja) * | 2013-10-23 | 2017-03-09 | 中外製薬株式会社 | キナゾリノンおよびイソキノリノン誘導体 |
US10005739B2 (en) | 2013-10-23 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
WO2018171726A1 (zh) * | 2017-03-23 | 2018-09-27 | 高雄医学大学 | 盘基蛋白结构域受体1的抑制剂及活化剂及其用途 |
US10946021B2 (en) | 2017-03-23 | 2021-03-16 | Kaohsiung Medical University | Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1) |
WO2021239643A1 (en) | 2020-05-25 | 2021-12-02 | Chiesi Farmaceutici S.P.A. | Benzylamine derivatives as ddrs inhibitors |
EP4032896A1 (en) | 2021-01-20 | 2022-07-27 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof |
WO2022157166A1 (en) | 2021-01-20 | 2022-07-28 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof |
WO2023210599A1 (ja) * | 2022-04-25 | 2023-11-02 | 日本新薬株式会社 | Ddr1キナーゼ阻害剤としての化合物および医薬 |
Also Published As
Publication number | Publication date |
---|---|
KR20100060300A (ko) | 2010-06-07 |
WO2010062038A3 (ko) | 2010-07-22 |
KR101126736B1 (ko) | 2012-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010062038A2 (ko) | 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 | |
WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
MX2009013077A (es) | Derivados dde benzoxazolona. | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
MX2007015863A (es) | Inhibidores de esfingosina cinasa. | |
UA94622C2 (en) | Kinase innhibitor | |
WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
WO2007019251A3 (en) | Sphingosine kinase inhibitors and methods of their use | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
WO2005111039A3 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
WO2011052923A3 (en) | Novel 1,6-disubstituted indole compounds as protein kinase inhibitors | |
EP2134346A4 (en) | INHIBITORS OF JANUS KINASES AND / OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 | |
PL1899329T3 (pl) | Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych | |
WO2008118391A3 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
WO2010017545A3 (en) | Triazole compounds that modulate hsp90 activity | |
WO2008021038A3 (en) | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | |
MX2012013197A (es) | Inhibidores de indazol de cinasa. | |
NZ623069A (en) | Heat shock protein binding compounds, compositions, and methods for making and using same | |
WO2008011557A3 (en) | Heteroaryl inhibitors of rho kinase | |
MY148634A (en) | Pyridazinone derivatives | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
MX2011013325A (es) | 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09829245 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.08.11 AND 02.09.11) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09829245 Country of ref document: EP Kind code of ref document: A2 |